Shrestha Asis, Alzubi Marah, Alrawabdeh Jawad, Schinke Carolina, Thanendrarajan Sharmilan, Zangari Maurizio, van Rhee Frits, Al Hadidi Samer
Department of Hematology/Oncology Myeloma Center Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences Little Rock Arkansas USA.
Department of Medicine, School of Medicine University of Jordan Amman Jordan.
EJHaem. 2024 Apr 16;5(3):554-559. doi: 10.1002/jha2.896. eCollection 2024 Jun.
Talquetamab recently received approval for relapsed refractory multiple myeloma. However, there is currently no available data on how patients perform with BCMA based agents after progression on talquetamab. Herein, we present the outcome of 10 patients who received BCMA based therapies following talquetamab. The median follow-up was 9.5 months (range: 6-24 months). The median progression free survival was 5.5 months (range: 1-10 months). Patients had varying grades of cytokine release syndrome and Immune effector cell-associated neurotoxicity syndrome. Our results suggest that treatment with talquetamab followed by BCMA based therapies is feasible and can be considered as clinically indicated.
talquetamab最近获批用于复发难治性多发性骨髓瘤。然而，目前尚无关于患者在talquetamab治疗进展后使用基于BCMA的药物的表现的数据。在此，我们报告了10例在talquetamab治疗后接受基于BCMA治疗的患者的结果。中位随访时间为9.5个月（范围：6 - 24个月）。中位无进展生存期为5.5个月（范围：1 - 10个月）。患者出现了不同程度的细胞因子释放综合征和免疫效应细胞相关神经毒性综合征。我们的结果表明，先使用talquetamab治疗，随后使用基于BCMA的疗法是可行的，可作为临床指征考虑。
